Remimazolam alleviates myocardial injury of rats with myocardial ischemia-reperfusion

doi:10.16352/j.issn.1001-6325.2024.09.1243

Abstract

Abstract: Objective To investigate the effect of remimazolam (RE) on myocardial injury in myocardial ischemia-reperfusion (MI/R) rats and its mechanism. Methods The MI/R rat model was constructed and divided into sham group, MI/R model group, RE low, medium, high dose group (RE-L, RE-M, RE-H group)and Yes associated protein(YAP) inhibitor verteporfin group. Left ventricular ejection fraction (LVEF) and left ventricular fractional shortening(LVFS) were recorded in each group and commercially available kit was applied to detect the level of myocardial injury marker like LDH, c-TnI and CK-MB. The size of myocardial infarction was evaluated by TTC staining. Pathological changes in myocardial tissue was microscopied by HE staining.The apoptosis of myocardial cell was observed by TUNEL method. Expression of Hippo/YAP signaling pathway proteins in myocardial tissue was detected by Western blot. Results Compared to the sham surgery group, the myocardial structure of rats in the model group was disrupted,myocardial cells were reduced, the LVFS and LVEF were decreased, the expression of YAP was greatly reduced. The level of serum LDH, CK-MB, cTnI, myocardial infarction area, myocardial cell apoptosis rate, p-MST1/MST1, p-LATS1/LATS1 and p-YAP expression were all significantly increased(P＜0.05); As compared to model group, the pathological change in myocardial tissue of rats in the low, medium, and high-dose RE groups was greatly reduced. The LVFS and LVEF were increased. The expression of YAP was significantly increased. The serum level of LDH, CK-MB, cTnI, the myocardial infarction area, myocardial cell apoptosis rate, p-MST1/MST1, p-LATS1/LATS1 and p-YAP expression were evidently reduced (P＜0.05). The YAP inhibitor verteporfin reversed the improvement effect of RE on myocardial injury in MI/R rats. Conclusions RE may improve cardiac function in MI/R rats, alleviate myocardial infarction and myocardial cell apoptosis and inhibit myocardial injury by regulating the Hippo/YAP signaling pathway.

Key words: myocardial ischemia-reperfusion, myocardial injury, remimazolam, Hippo/Yes associated protein

CLC Number:

R614

ZHEN Lei, ZHANG Yilan, WANG Xiaona, ZHANG Xiaoqiong. Remimazolam alleviates myocardial injury of rats with myocardial ischemia-reperfusion[J]. Basic & Clinical Medicine, 2024, 44(9): 1243-1248.

References 15

[1]	Algoet M, Janssens S, Himmelreich U, et al. Myocardial ischemia-reperfusion injury and the influence of inflammation[J]. Trends Cardiovasc Med, 2023, 33:357-366.
[2]	Yang H, Xue W, Ding C, et al. Vitexin mitigates myocardial ischemia/reperfusion injury in rats by regulating mitochondrial dysfunction via Epac1-Rap1 signaling[J]. Oxid Med Cell Longev, 2021, 2021:9921982. doi: 10.1155/2021/9921982.
[3]	Hu Q, Liu X, Wen C, et al. Remimazolam: an updated review of a new sedative and anaesthetic[J]. Drug Des Devel Ther, 2022, 16:3957-3974.
[4]	Xu H, Chen Y, Xie P, et al. Remimazolam attenuates myocardial ischemia-reperfusion injury by inhibiting the NF-κB pathway of macrophage inflammation[J]. Eur J Pharmacol, 2023, 17:176276. doi: 10.1016/j.ejphar.2023.176276.
[5]	Zheng A, Chen Q, Zhang L. The Hippo-YAP pathway in various cardiovascular diseases: focusing on the inflammatory response[J]. Front Immunol, 2022, 13:971416. doi: 10.3389/fimmu.2022.971416.
[6]	Niu J, Li Y, Song X, et al. Cardioprotective effect of echinatin against ischemia/reperfusion injury: involve-ment of Hippo/Yes-associated protein signaling[J]. Front Pharmacol, 2021, 11:593225. doi: 10.3389/fphar.2020.593225.
[7]	陈兴华, 韩露, 贡鸣, 等. 落新妇苷对大鼠心肌缺血再灌注损伤的影响及机制[J]. 中国药房, 2023, 34:1193-1198, 1203.
[8]	Chen Z, Wu J, Li S, et al. Inhibition of myocardial cell apoptosis is important mechanism for ginsenoside in the limitation of myocardial ischemia/reperfusion injury[J]. Front Pharmacol, 2022, 13:806216. doi: 10.3389/fphar.2022.806216.
[9]	郑新, 于海波. miR-146a减轻心肌缺血/再灌注损伤(MI/RI)大鼠的心肌细胞凋亡[J].基础医学与临床, 2021, 41:1756-1761. doi: 10.16352/j.issn.1001-6325.2021.12.010.
[10]	Zhang Q, Peng Y, Liu J, et al. 7-Hydroxyflavone alleviates myocardial ischemia/reperfusion injury in rats by regulating inflammation[J]. Molecules, 2022, 27:5371. doi: 10.3390/molecules27175371.
[11]	Ding W, Peng H, Tian J, et al. Remimazolam relieved the injury of hypoxia/reperfusion treated human embryo liver cell line through the targeting METTL3 mediated m6A modification of p53[J]. Heliyon, 2023, 9:e20285. doi: 10.1016/j.heliyon.2023.e20285.
[12]	Shi M, Chen J, Liu T, et al. Protective effects of remimazolam on cerebral ischemia/reperfusion injury in rats by inhibiting of NLRP3 inflammasome-dependent pyroptosis[J]. Drug Des Devel Ther, 2022, 16:413-423.
[13]	Yu H, Tang H, Deng C, et al. RRM2 improves cardiomyocyte proliferation after myocardial ischemia reperfusion injury through the Hippo-YAP pathway[J]. Dis Markers, 2021, 2021:5089872. doi: 10.1155/2021/5089872.
[14]	Tian H, Xiong Y, Xia Z. Resveratrol ameliorates myocardial ischemia/reperfusion induced necroptosis through inhibition of the Hippo pathway[J]. J Bioenerg Biomembr, 2023, 55:59-69.
[15]	Qiu M, Yan W, Liu M. YAP facilitates NEDD4L-mediated ubiquitination and degradation of ACSL4 to alleviate ferroptosis in myocardial ischemia-reperfusion injury[J]. Can J Cardiol, 2023, 39:1712-1727.